Fig. 4: Batf3-dependent cDC1s are required for IV BCG efficacy against B16-F10 lung metastases.

a Schematic diagram showing treatment strategy for (a–e) and absolute number and frequency of cDC1s in the lung (n = 18 mice per group, pooled from three independent experiments). b Flow cytometry quantification of CD86, CD40 and XCR1 mean fluorescence intensity (MFI) on lung cDC1s (n = 11 mice/group for CD86, n = 9 mice/group for CD40 and n = 14 mice/group for XCR1, pooled from four independent experiments). c IL-12 expression by lung cDC1s after ex vivo restimulation (n = 6 mice per group, from one experiment). d Absolute number of cDC1s in the lung-draining mediastinal lymph node (mLN) (n = 9 mice per group, pooled from two independent experiments). e CD86, CD40 and XCR1 expression by mLN cDC1s (n = 6 mice per group, pooled from two independent experiments). f Schematic diagram showing treatment strategy for (f–i) and quantification of B16-F10-gp33 lung surface metastases (n = 8 mice/group for WT mice and n = 10 mice/group for Batf3−/−, pooled from two independent experiments). g Lung CD8+ T frequency in B16-F10-gp33 lung tumor bearing mice (n = 6 mice/group for WT mice and n = 10 mice/group for Batf3−/−, pooled from two independent experiments). h Quantification of CD44+ gp33-specific CD8+ T cells in the lungs. Representative contour plots are shown. n = 6 mice/group for WT mice and n = 10 mice/group for Batf3−/− mice, pooled from two independent experiments. i Cytotoxicity exerted by splenocytes isolated from the indicated groups of mice bearing B16-F10-gp33 lung tumors against target B16-F10-ZsGreenLuc or LLC-ZsGreenLuc tumor cells. n = 6 mice/group, from one experiment. j Therapeutic efficacy of IV BCG in Batf3−/− mice bearing B16-F10 lung tumors (n = 7 mice/group, pooled from two independent experiments). P values were calculated using two-tailed unpaired Student’s t test at a 95 % CI (a–e), one-way ANOVA with Bonferroni multiple-comparison test (f–i) or log-rank (Mantel-Cox) test (j). Data is depicted as mean ± SEM (a–i). PBS phosphate-buffered saline, IV intravenous, cDC1s type 1 conventional dendritic cells, mLN mediastinal lymph node.